Difference between revisions of "Team:Freiburg/Proof"
| Line 198: | Line 198: | ||
</div> | </div> | ||
<div class='txt2Div'> | <div class='txt2Div'> | ||
| − | <div>We verified the display of heterologous proteins containing an epitope tag on the surface of the spores by immunostaining and flow cytometry analysis. Read more about the production of Nanocillus. | + | <div>We verified the display of heterologous proteins containing an epitope tag on the surface of the spores by immunostaining and flow cytometry analysis. Read more about the production of Nanocillus. <br> |
| + | Click <a href="https://2016.igem.org/Team:Freiburg/Production_Nanocillus" target="_blank" style="text-align: center;font-size:20px;color:#e8a126">here</a> for more information. | ||
</div> | </div> | ||
| Line 224: | Line 225: | ||
</div> | </div> | ||
<div class='txt2Div'> | <div class='txt2Div'> | ||
| − | <div>The anti-GFP nanobody was fusion on spore coat proteins and displayed on their surface. We verified the binding of the target GFP to the displayed nanobody by flow cytometry analysis. Learn more about targeting. | + | <div>The anti-GFP nanobody was fusion on spore coat proteins and displayed on their surface. We verified the binding of the target GFP to the displayed nanobody by flow cytometry analysis. Learn more about targeting.<br> |
| + | Click <a href="https://2016.igem.org/Team:Freiburg/Targeting" target="_blank" style="text-align: center;font-size:20px;color:#e8a126">here</a> for more information. | ||
| + | |||
| + | |||
</div> | </div> | ||
</div> | </div> | ||
| Line 252: | Line 256: | ||
<div class='txt2Div'> | <div class='txt2Div'> | ||
<div>Glutathione S-transferase converts the prodrug azathioprine to its active form 6-mercaptopurine. We displayed the enzyme on the spore surface and validated its functionality by a colorimetric GST assay. Read more about the drug delivery. | <div>Glutathione S-transferase converts the prodrug azathioprine to its active form 6-mercaptopurine. We displayed the enzyme on the spore surface and validated its functionality by a colorimetric GST assay. Read more about the drug delivery. | ||
| + | |||
| + | <br> | ||
| + | Click <a href="https://2016.igem.org/Team:Freiburg/Delivery" target="_blank" style="text-align: center;font-size:20px;color:#e8a126">here</a> for more information. | ||
</div> | </div> | ||
</div> | </div> | ||
Revision as of 22:53, 18 October 2016
Proof of Concept
We produced a carrier that is suitable for the display of proteins on its surface.
We were able to produce engineered spores from B. subtilis and establish protocols for its purification.
We verified the display of heterologous proteins containing an epitope tag on the surface of the spores by immunostaining and flow cytometry analysis. Read more about the production of Nanocillus.
Click here for more information.
Click here for more information.
We achieved the display of nanobodies as binding moiety and showed their functionality towards a target.
The anti-GFP nanobody was fusion on spore coat proteins and displayed on their surface. We verified the binding of the target GFP to the displayed nanobody by flow cytometry analysis. Learn more about targeting.
Click here for more information.
Click here for more information.
We accomplished the display of functional glutathione S-transferase on the spores, an enzyme playing a crucial role in the activation of prodrugs.
Glutathione S-transferase converts the prodrug azathioprine to its active form 6-mercaptopurine. We displayed the enzyme on the spore surface and validated its functionality by a colorimetric GST assay. Read more about the drug delivery.
Click here for more information.
Click here for more information.
